Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U.

Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276.

PMID:
22967994
2.

Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.

Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T; other Knowledge Network members..

Endocr Relat Cancer. 2015 Aug;22(4):657-64. doi: 10.1530/ERC-15-0119.

3.

Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.

Terashima T, Morizane C, Hiraoka N, Tsuda H, Tamura T, Shimada Y, Kaneko S, Kushima R, Ueno H, Kondo S, Ikeda M, Okusaka T.

Neuroendocrinology. 2012;96(4):324-32. doi: 10.1159/000338794.

PMID:
22572060
4.

Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.

Kamboj M, Gandhi JS, Gupta G, Sharma A, Pasricha S, Mehta A, Chandragouda D, Sinha R.

J Gastrointest Cancer. 2015 Dec;46(4):356-64. doi: 10.1007/s12029-015-9745-9. Review.

PMID:
26208508
5.

Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.

Crippa S, Partelli S, Bassi C, Berardi R, Capelli P, Scarpa A, Zamboni G, Falconi M.

Surgery. 2016 Mar;159(3):862-71. doi: 10.1016/j.surg.2015.09.012.

PMID:
26602841
6.

Gastroenteropancreatic high-grade neuroendocrine carcinoma.

Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC.

Cancer. 2014 Sep 15;120(18):2814-23. doi: 10.1002/cncr.28721. Review.

7.
8.

Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.

Boo YJ, Park SS, Kim JH, Mok YJ, Kim SJ, Kim CS.

J Surg Oncol. 2007 Feb 1;95(2):110-7.

PMID:
17066436
9.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Loriot Y, Duvillard P, Chougnet CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E.

Endocr Relat Cancer. 2015 Jun;22(3):289-98. doi: 10.1530/ERC-15-0075.

10.

Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience.

Tondini C, Giardini R, Bozzetti F, Valagussa P, Santoro A, Bertulli R, Balzarotti M, Rocca A, Lombardi F, Ferreri AJ, et al.

Ann Oncol. 1993 Dec;4(10):831-7.

PMID:
8117602
11.

Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.

Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MB, Cellerino R, Piga A.

Am J Clin Oncol. 2002 Apr;25(2):140-8.

PMID:
11943891
12.

Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?

Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutumi H, Fujiyoshi T, Sato T, Hieda N, Yoshida T, Okuno N, Shimizu Y, Yatabe Y, Niwa Y, Yamao K.

J Gastroenterol. 2015 May;50(5):564-72. doi: 10.1007/s00535-014-0987-2.

13.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H.

J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534. Erratum in: J Clin Oncol. 2010 Jan 1;28(1):182. Winquist, Eric [added].

PMID:
19687335
14.

Chemotherapy versus best supportive care for extensive small cell lung cancer.

Pelayo Alvarez M, Westeel V, Cortés-Jofré M, Bonfill Cosp X.

Cochrane Database Syst Rev. 2013 Nov 27;(11):CD001990. doi: 10.1002/14651858.CD001990.pub3. Review.

PMID:
24282143
15.

Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus.

Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL.

Am J Surg Pathol. 2008 Sep;32(9):1404-11. doi: 10.1097/PAS.0b013e31816bf41f.

PMID:
18670347
16.

Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification.

Lee JL, Yu CS, Kim M, Hong SM, Lim SB, Kim JC.

Surgery. 2014 Apr;155(4):650-8. doi: 10.1016/j.surg.2013.11.012.

PMID:
24468036
17.

Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.

Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, Solcia E, Capella C, Sessa F, La Rosa S.

Endocr Relat Cancer. 2015 Feb;22(1):35-45. doi: 10.1530/ERC-14-0410.

18.

Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues.

Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R, Manfredi S, Tougeron D, Desseigne F, Lourenco N, Afchain P, El Hajbi F, Terris B, Rougier P, Coriat R.

Medicine (Baltimore). 2015 Oct;94(42):e1864. doi: 10.1097/MD.0000000000001864.

19.

The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.

Crosara Teixeira M, Marques DF, Ferrari AC, Alves MF, Alex AK, Sabbaga J, Hoff PM, Riechelmann RP.

Clin Colorectal Cancer. 2015 Mar;14(1):52-7. doi: 10.1016/j.clcc.2014.09.010.

PMID:
25442812
20.
Items per page

Supplemental Content

Support Center